Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.045
+0.005 (0.12%)
Jul 24, 2026, 1:54 PM EDT - Market open

Protara Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-70.05-64.55-49.15-43.61-67.06-47.49
Net Income
-63.31-57.44-44.6-40.42-65.95-47.25
Earnings Per Share
-1.34-1.34-2.17-3.57-5.86-4.21
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
135.79155.55170.2965.5884.3791.23
Total Debt
3.063.364.485.476.387.24
Net Cash (Debt)
132.73152.2165.8160.1177.9983.99
Net Cash Growth
10.48%-8.21%175.83%-22.92%-7.15%-49.86%
Net Cash Per Share
2.823.558.055.316.937.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-63-56.37-35.81-37.56-26.46-34.5
Capital Expenditures
-0.05-0.09-0.06-0.05-0.12-0.6
Free Cash Flow
-63.05-56.46-35.87-37.6-26.58-35.1
Free Cash Flow Growth
------